A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication

Minodora Andor,1,* Liana Dehelean,2,* Ana-Maria Romosan,2,* Valentina Buda,3 Gabriela Radu,1 Florina Caruntu,1 Aurora Bordejevic,1 Minodora Marinela Manea,4 Ion Papava,2 Cristina Ana Bredicean,2 Radu Stefan Romosan,2 Mirela Tomescu1 1Medical Semiology II, Department of Internal Medicine I, &ldq...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andor M, Dehelean L, Romosan AM, Buda V, Radu G, Caruntu F, Bordejevic A, Manea MM, Papava I, Bredicean CA, Romosan RS, Tomescu M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	schizophrenic patients speckle tracking echocardiography myocardial dysfunction Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7f74a1742f6b4a78aac0f22346973fc7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7f74a1742f6b4a78aac0f22346973fc7
record_format	dspace
spelling	oai:doaj.org-article:7f74a1742f6b4a78aac0f22346973fc72021-12-02T04:36:03ZA novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication1178-2021https://doaj.org/article/7f74a1742f6b4a78aac0f22346973fc72019-01-01T00:00:00Zhttps://www.dovepress.com/a-novel-approach-to-cardiovascular-disturbances-in-patients-with-schiz-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Minodora Andor,1,* Liana Dehelean,2,* Ana-Maria Romosan,2,* Valentina Buda,3 Gabriela Radu,1 Florina Caruntu,1 Aurora Bordejevic,1 Minodora Marinela Manea,4 Ion Papava,2 Cristina Ana Bredicean,2 Radu Stefan Romosan,2 Mirela Tomescu1 1Medical Semiology II, Department of Internal Medicine I, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 2Discipline of Psychiatry, Department of Neurosciences, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 3Pharmacology and Clinical Pharmacology, 2nd Department, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 4Department of Psychology, Medical Education, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania *These authors contributed equally to this work and thus share first authorship Purpose: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone).Patients and methods: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients’ clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography.Results: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients’ myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone.Conclusion: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication. Keywords: schizophrenic patients, speckle tracking echocardiography, myocardial dysfunctionAndor MDehelean LRomosan AMBuda VRadu GCaruntu FBordejevic AManea MMPapava IBredicean CARomosan RSTomescu MDove Medical Pressarticleschizophrenic patientsspeckle tracking echocardiographymyocardial dysfunctionNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 349-355 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenic patients speckle tracking echocardiography myocardial dysfunction Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	schizophrenic patients speckle tracking echocardiography myocardial dysfunction Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Andor M Dehelean L Romosan AM Buda V Radu G Caruntu F Bordejevic A Manea MM Papava I Bredicean CA Romosan RS Tomescu M A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
description	Minodora Andor,1,* Liana Dehelean,2,* Ana-Maria Romosan,2,* Valentina Buda,3 Gabriela Radu,1 Florina Caruntu,1 Aurora Bordejevic,1 Minodora Marinela Manea,4 Ion Papava,2 Cristina Ana Bredicean,2 Radu Stefan Romosan,2 Mirela Tomescu1 1Medical Semiology II, Department of Internal Medicine I, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 2Discipline of Psychiatry, Department of Neurosciences, “Victor Babeş” University of Medicine and Pharmacy, Timisoara, Romania; 3Pharmacology and Clinical Pharmacology, 2nd Department, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 4Department of Psychology, Medical Education, “Iuliu Haţieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania *These authors contributed equally to this work and thus share first authorship Purpose: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone).Patients and methods: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients’ clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography.Results: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients’ myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone.Conclusion: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication. Keywords: schizophrenic patients, speckle tracking echocardiography, myocardial dysfunction
format	article
author	Andor M Dehelean L Romosan AM Buda V Radu G Caruntu F Bordejevic A Manea MM Papava I Bredicean CA Romosan RS Tomescu M
author_facet	Andor M Dehelean L Romosan AM Buda V Radu G Caruntu F Bordejevic A Manea MM Papava I Bredicean CA Romosan RS Tomescu M
author_sort	Andor M
title	A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_short	A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_full	A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_fullStr	A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_full_unstemmed	A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
title_sort	novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/7f74a1742f6b4a78aac0f22346973fc7
work_keys_str_mv	AT andorm anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT deheleanl anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosanam anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT budav anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT radug anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT caruntuf anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT bordejevica anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT maneamm anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT papavai anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT brediceanca anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosanrs anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT tomescum anovelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT andorm novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT deheleanl novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosanam novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT budav novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT radug novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT caruntuf novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT bordejevica novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT maneamm novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT papavai novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT brediceanca novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT romosanrs novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication AT tomescum novelapproachtocardiovasculardisturbancesinpatientswithschizophreniaspectrumdisorderstreatedwithlongactinginjectablemedication
_version_	1718401130380132352

A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication

Ejemplares similares